Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of ADXS stock opened at $0.04 on Tuesday. The firm has a fifty day moving average of $0.04 and a 200-day moving average of $0.04. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.78. The company has a market capitalization of $1.71 million, a price-to-earnings ratio of -0.01 and a beta of 1.18.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.